Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Mol Cancer Res. 2021 Jun 22;19(10):1651–1665. doi: 10.1158/1541-7786.MCR-20-0994

Figure 7. Nestin deficiency sensitizes GBM cells to vinblastine.

Figure 7

U251 cells (a), GBM PDX1 cells (b) and PDX2 cells (c) were virally infected with Nestin shRNA (shNes) or scrambled shRNA (shCtrl). At 96 hrs following the infection, cells were treated with etoposide (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM), vinblastine (1.5 nM, 3 nM, 5 nM, 10 nM, 20 nM) or vincristine (0.2 nM, 1.2 nM, 2.5 nM, 5 nM, 10 nM, 50 nM) for 48 hrs. The cell viability was measured by CCK8 assay, and plotted against the concentrations. IC50 of vinblastine and etoposide in GBM cells was quantified. Drug responses of Nestin deficient cells and control cells were compared by Log-rank test.